Kidney Cancer Association Applauds UK Drug Approval

      Change of Tack Shows Policy Shift and Saves Lives Evanston, IL, February 5, 2009 – The National Institute of Health and Clinical Excellence (NICE), the review body for the UK’s National Health Service, yesterday reversed an earlier decision and approved a drug for metastatic renal cell carcinoma. The decision marks an enormous victory for advanced-stage kidney cancer patients as well as the advocates who applied pressure on NICE to change their policy regarding lifesaving drugs for terminal patients.   “This decision demonstrates the power of a unified voice,” said William Bro, president of the Kidney Cancer Association. “Patient advocates won’t sit back and watch decisions be made about their loved ones lives based on cost, not science. This drug and the three others still being reviewed are proven to be effective and we are delighted that thousands of deserving patients in the U.K. finally have access to life-saving drugs.”   The drug, sunitinib (Sutent) is a novel, oral treatment that shows overall survival greater than two years in advanced kidney cancer patients. In September 2008, NICE advised against the use of Sutent and three other drugs (Avastin, Nexavar and Torisel). The decision reflects a change in policy guidelines that give greater consideration to the value that society places on end-of-life treatments.   “The risk you run with a single payer system s...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

Santosh K. Ghosh1*, Thomas S. McCormick1,2 and Aaron Weinberg1* 1Biological Sciences, School of Dental Medicine, Case Western Reserve University, Cleveland, OH, United States 2Dermatology, School of Medicine, Case Western Reserve University, Cleveland, OH, United States Human beta-defensins (hBDs, −1, 2, 3) are a family of epithelial cell derived antimicrobial peptides (AMPs) that protect mucosal membranes from microbial challenges. In addition to their antimicrobial activities, they possess other functions; e.g., cell activation, proliferation, regulation of cytokine/chemokine production, migration, diffe...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Hui Zhou, Xiaoyan Fu, Qian Li and Ting Niu* Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, Chengdu, China Background: Immune checkpoint inhibition therapy with monoclonal antibody against programmed cell death protein 1 (PD-1), including nivolumab and pembrolizumab, has demonstrated powerful clinical efficacy in the treatment of advanced cancers. However, there is no evidence-based systematic review on the safety and efficacy of anti-PD-1 antibody in treating lymphoma. Methods: To evaluate the safety and efficacy of nivolumab/pembrolizumab, we analyzed clin...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Li Liu, Jiajing Lin and Hongying He* Department of Obstetrics and Gynecology, Liuzhou Worker’s Hospital, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China Background and Objective: Endometrial cancer (EC) is a common gynecological malignancy worldwide. Despite advances in the development of strategies for treating EC, prognosis of the disease remains unsatisfactory, especially for advanced EC. The aim of this study was to identify novel genes that can be used as potential biomarkers for identifying the prognosis of EC and to construct a novel risk stratification using these genes. Me...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
This study aimed to investigate whether combining anti-PD-L1 Atezolizumab with BEV may have a synergistic effect and enhance the efficacy of both treatments in cisplatin resistant epithelial ovarian cancer (CREOC). We retrospectively analyzed 124 epithelial ovarian cancer (EOC) patients from Gynecologic Oncology Department of Tianjin Cancer Hospital between January 2013 and June 2018, who all were diagnosed with cisplatin resistance due to progressing
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Eleonora A. Braga1*†, Marina V. Fridman2†, Vitaly I. Loginov1,3, Alexey A. Dmitriev4 and Sergey G. Morozov1 1Institute of General Pathology and Pathophysiology, Moscow, Russia 2Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia 3Research Center of Medical Genetics, Moscow, Russia 4Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia Clear cell renal cell carcinoma (ccRCC) is the third most common urological cancer, and it has the highest mortality rate. The increasing drug resistance of metastatic ccRCC has resulted in the search f...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Iliana Claudia Balga Milian1, Rafaela José Silva1, Camilla Manzan-Martins1, Bellisa Freitas Barbosa1, Pamela Mendonça Guirelli1, Mayara Ribeiro1, Angelica de Oliveira Gomes2, Francesca Ietta3, José Roberto Mineo4, Priscila Silva Franco1 and Eloisa Amália Vieira Ferro1* 1Laboratory of Immunophysiology of Reproduction, Institute of Biomedical Science, Federal University of Uberlândia, Uberlândia, Brazil 2Department of Morphology, Federal University of the Triângulo Mineiro, Uberaba, Brazil 3Department of Life Sciences, University of Siena, Siena, Italy 4Laboratory of I...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Gui-Jiang Wei1,2, Ming-Qing Yuan1, Li-He Jiang1, Yu-Lan Lu3, Chun-Hong Liu3, Hong-Cheng Luo3, Hua-Tuo Huang3, Zong-Quan Qi1* and Ye-Sheng Wei1,2* 1Department of Cell Biology, Medical College of Guangxi University, Nanning, China 2Department of Medical Laboratory, Affiliated Hospital of Guilin Medical University, Guilin, China 3Department of Medical Laboratory, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China miRNAs are small non-coding RNAs modulating gene expression, and variants in miRNA genes are involved in the pathogenesis of ischemic stroke (IS). However, the effect of mi...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Conclusion: Higher pretreatment RDW levels were demonstrated to be associated with poor clinical outcome in male LSCC patients and might be novel markers for patient stratification in LSCC management. Introduction Laryngeal cancer is one of the most common cancers of the head and neck, of which the estimated crude incidence and mortality rates in China were 1.86/100,000 and 1.01/100,000, respectively (1). This disease has a male predominance with a male-to-female ratio of 20 to 30:1 in China (2). The most commonly observed histological type of laryngeal cancer is laryngeal squamous cell cancer (LSCC), accounting for ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, T cells deficient in TRAF6 display enhanced T cell activation, CD28-indpendent stimulation and resistance to Treg cell-mediated suppression (176). Although TLR signaling can promote T cell resistance to Treg cells, the precise molecular mechanism remains yet to be elucidated. It is worth noting that TLR stimulation of T cells increases cytokine production (173, 177), thus future studies should delineate the effect of TLR-MyD88 signaling vs. subsequently induced cytokines in generating resistance to Treg cells. Lastly, it is also crucial to evaluate the effect of TLR signaling on regulatory T cells which also...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Federico Altieri1, Tommy V. Hansen2 and Fabio Vandin1* 1Department of Information Engineering, University of Padova, Padova, Italy 2Department of Mathematics and Computer Science, University of Southern Denmark, Odense, Denmark Next-generation sequencing technologies allow to measure somatic mutations in a large number of patients from the same cancer type: one of the main goals in their analysis is the identification of mutations associated with clinical parameters. The identification of such relationships is hindered by extensive genetic heterogeneity in tumors, with different genes mutated in different patien...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Health | Kidney Cancer | Lessons | National Health Service (NHS) | National Institute for Health and Clinical Excelle | National Institutes of Health (NIH) | Oral Cancer | Renal Cell Carcinoma | Science | UK Health | Urology & Nephrology